The Investor Manifesto
Advertisement
  • Business
  • Politics
  • Investing
  • Stocks
No Result
View All Result
  • Business
  • Politics
  • Investing
  • Stocks
No Result
View All Result
The Investor Manifesto
No Result
View All Result
Home Investing

Placement to Support Next Phases of Grandis Project

July 25, 2024
in Investing
Placement to Support Next Phases of Grandis Project
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

Elixir Energy Limited (Elixir or the Company) is pleased to announce that it has received binding commitments for a placement of new shares in the Company (Placement), on the following terms:

1. Placement to raise $6.25 million (before costs) through the issue of 62.5 million new shares to institutional and sophisticated investors at a price of 10 cents per share (a 13% discount to the last close and a 12.7% discount to the 5 day VWAP).

2. Placement participants will receive one (1) one of Elixir’s currently listed options (EXROBs) for every four (4) Placement Shares issued. These already listed EXROB Options have an exercise price of 12 cents and a term expiring on 17 October 2026.

HIGHLIGHTS

Over-subsribed share placement of $6.25 million to institutional and sophisticated investorsFunds to be used to support the next phases of the Grandis Project

The capital raising was strongly supported, with demand in excess of the placement size, and introduced a number of new institutional investors to the Company’s register.

The new capital raised will be deployed in the next phases of the Grandis Project – to deal with potential contingencies that might arise from the imminent multiple stage stimulation and flow testing program at the Company’s Daydream-2 well; and, position the Company for the next phases of Project Grandis – including ordering long lead items for the next well and improving the negotiating position for potential farm-out negotiations post the flow testing phase.

The 62.5 million Placement Shares will be issued under listing rule 7.1 A and the 18,750,000 Listed Options will be issued under listing rule 7.1.

The new shares are anticipated to be issued on Wednesday, 31 July 2024.

Taylor Collison Limited and Originate Capital Pty Ltd acted as Joint Lead Managers to the Placement.

Elixir’s Managing Director, Mr. Neil Young, said: “We are pleased to receive this financial support from existing and new investors to fund the final phases of the Daydream-2 program and take forward Project Grandis into its next phases. Equipment is mobilizing to the well lease and the commencement of work is now imminent.”

Click here for the full ASX Release

This post appeared first on investingnews.com

Previous Post

Crypto Market Buzzing on Rumor Trump Will Announce Bitcoin as Strategic Reserve Asset

Next Post

Sams Creek and Reefton Exploration Update

Next Post
Sams Creek and Reefton Exploration Update

Sams Creek and Reefton Exploration Update

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent News

    Is a Bold Rotation Brewing in Healthcare and Biotech? Here’s What to Watch Now

    Is a Bold Rotation Brewing in Healthcare and Biotech? Here’s What to Watch Now

    June 14, 2025
    Bearish Divergence Suggests Caution For S&P 500

    Bearish Divergence Suggests Caution For S&P 500

    June 14, 2025
    Nearly half of Americans back Israeli airstrikes on Iran, poll shows

    Nearly half of Americans back Israeli airstrikes on Iran, poll shows

    June 14, 2025
    ‘All-in’: GOP lawmakers divided on US involvement as Trump pushes Iran for diplomatic end

    ‘All-in’: GOP lawmakers divided on US involvement as Trump pushes Iran for diplomatic end

    June 14, 2025
    Disclaimer: TheInvestorManifesto.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Popular

    Radiopharm Theranostics Granted U.S. Food and Drug Administration Fast Track Designation for RAD101 Imaging in Brain Metastases
    Investing

    Radiopharm Theranostics Granted U.S. Food and Drug Administration Fast Track Designation for RAD101 Imaging in Brain Metastases

    June 11, 2025

    Read more

    Recent News

    Is a Bold Rotation Brewing in Healthcare and Biotech? Here’s What to Watch Now

    Is a Bold Rotation Brewing in Healthcare and Biotech? Here’s What to Watch Now

    June 14, 2025
    Bearish Divergence Suggests Caution For S&P 500

    Bearish Divergence Suggests Caution For S&P 500

    June 14, 2025
    • About us
    • Contacts
    • Privacy Policy
    • Terms and Conditions
    • Email Whitelisting

    Copyright © 2025 theinvestormanifesto.com | All Rights Reserved

    No Result
    View All Result
    • Business
    • Politics
    • Investing
    • Stocks

    Copyright © 2025 theinvestormanifesto.com | All Rights Reserved